2-Year Overall Survival Results From DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

Ladha et al. • 2026 • NEALS

Read more

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

Andrews, et al. • 2025 • NEALS 2025

Read more

DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

van den Berg et al. • 2025 • ENCALS 2025 Congress

Read more

Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

Donaldson et al. • 2023 • NEALS 22nd Annual Meeting

Read more

https://corcept.com/wp-content/uploads/2023/01/ENCALS2023-1.pdf

Donaldson et al. • 2023 • ENCALS Meeting 2023

Read more

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

Mann et al • 2022 • European Network to Cure ALS (ENCALS)

Read more

Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

Webster et al. • 2017 • Br J Pharmacol. 2017;174(5):396-408.

Read more

The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice.

Meyer et al. • 2014 • J Steroid Biochem Mol Biol. 2014 Sep;143:40-8.

Read more

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube